Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: Preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2427-2432

  Behr, Thomas M ^a   Memtsoudis, Stavros ^b   Vougioukas, Vassilios ^b   Liersch, Torsten ^b   Gratz, Stefan ^b   Schmidt, Florian ^b   Lorf, Thomas ^b   Post, Stefan ^b   Wörmann, Bernhard ^b   Hiddemann, Wolfgang ^b   Ringe, Burckhardt ^b   Becker, Wolfgang ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NONE

Author keywords

17 1A antigen; 5 fluorouracil leucovorin; Carcinoembryonic antigen; Chemotherapy; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; IODINE RADIOISOTOPES; LEUCOVORIN; MICE; MICE, NUDE; PILOT PROJECTS; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 0032809407     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. DeVita VT, Hellman S, Rosenberg SA (eds.): Cancer - Principles and Practice of Oncology (5th edition). Philadelphia: Lippincott-Raven, 1997.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990.
3. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höfken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, The German cancer Aid 17-1A Study Group: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343: 1177-1183, 1994.
4. Göttlinger HG, Funke I, Johnson JP, Gokel JM, Riethmüller G: The epithelial surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38: 47-53, 1986.
5. Behr TM, Goldenberg DM, Becker WS: Radioimmunotherapy of solid tumors: a review "Of Mice and Men". Hybridoma 16: 101-107, 1997.
6. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329: 459-465, 1993.
7. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 346: 336-340, 1995.
8. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg, DM: Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 38: 409-418, 1997.
9. 125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res 49: 2952-2958, 1989.
10. Herlyn M, Steplewski Z, Herlyn D, Koprowski H: Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci 76: 1438-1442, 1979.
11. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 36: 430-441, 1995.
12. th Int Radiopharm Dosim Symp Gatlinburg (TN) 257-271, 1999.
13. 131I-labeled monoclonal antibodies, Cancer Res 52: 6036-6044, 1992.
14. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM: Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 54: 142-151, 1994.
15. 131I-labeled CO17-1A in a colorectal cancer model. Int J Cancer 76: 738-748, 1998.
16. Sharkey RM, Natale A, Goldenberg DM, Mattes MJ: Rapid blood clearance of immunoglobulin G2a in nude mice. Cancer Res 51: 3102-3107, 1991.
17. Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W: Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmuno-chemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57: 5309-5319, 1997.
18. Sharkey RM, Weadock KS, Natale A, Haywood L, Aninipot R, Blumenthal RD, Goldenberg DM: Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 83: 627-632, 1991.
19. Tschmelitsch J, Barendswaard E, Williams Jr C, Yao TJ, Cohen AM, Old LJ, Welt S: Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 57: 2181-2186, 1997.